LGD
8
0
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.5%
1 terminated/withdrawn out of 8 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection
Role: collaborator
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
Role: lead
Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants
Role: collaborator
Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients
Role: lead
Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity
Role: collaborator
Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.
Role: collaborator
Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults
Role: collaborator
Anti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus Placebo
Role: collaborator
All 8 trials loaded